New Merck-funded study on monthly HIV PrEP
New industry-funded study supported by Merck & Co., running through 2027: Monthly HIV Pre-Exposure Prophylaxis Preferences among U.S. Men Who Have Sex with Men. Pre-exposure prophylaxis (PrEP) is currently delivered either as a daily oral regimen or as a long-acting injectable given every two months, so a monthly formulation would sit between the two on dosing burden. The study measures how gay, bisexual, and other men who have sex with men weigh a monthly option against the formulations already available, then uses those preference estimates to parameterize a network transmission model. The modeling component estimates the population-level impact of a monthly formulation on HIV incidence relative to the current daily oral and injectable landscape.